Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin. A person inherits four genes to produce alpha globin protein and two genes to produce alpha globin protein from parents. —
Complete report on Global Thalassemia Market spread across 64 pages with providing 4 company profiles, 2 tables and 32 charts is now available at http://www.marketreportsonline.com/709193.html.
Key Company Coverage of Thalassemia Market: Bellicum Pharmaceuticals, Bluebird Bio, Celgene & GlaxoSmithKline Plc.
Thalassemia is caused by any abnormality or mutation in one or more genes responsible for hemoglobin production. When a person inherits only one affected gene from parents then the person becomes a carrier of thalassemia. Since, thalassemia is an inherited disorder; one of the parents must be a carrier for thalassemia. When both the parents are carriers then the risk of giving birth to a thalassemia affected child is quite high. Thalassemia is generally of two types: alpha thalassemia and beta thalassemia.
Purchase a copy of this “Global Thalassemia Market” research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=709193.
Globally, thalassemia affects approximately 7% of the population and many of them are transfusion dependent patients. The global thalassemia market is likely to be driven with the growing market of bone marrow transplant and blood transfusion therapy, supported by high numbers of transfusion dependent patients.
The U.S. is expected to be the first region to start selling of thalassemia drugs due to developing drug pipeline and later on, market penetration of thalassemia drugs would occur in Europe. U.S. and Europe have high prevalence of severe forms of beta-thalassemia which would result into a high demand for thalassemia drugs in future.
The global thalassemia market is expected to grow in future with mounting prevalence of thalassemia, rising Asian population, increasing healthcare expenditure, rising spending on pharmaceuticals R&D and stem cell therapy research. Key trends of this market include progressing drug pipeline, rising scope for gene therapy and growing awareness towards thalassemia. However, there are some factors which can hinder growth of the market including regulatory changes, associated risks and high cost of treatment.
This latest research report “Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including GlaxoSmithKline Plc, Celgene, Bluebird Bio and Bellicum Pharmaceuticals.
Major Points from Table of Contents Provided in Global Thalassemia Market Report:
1.2 Types of Thalassemia
1.3 Diagnosis and Treatment
2. Global Thalassemia Market
2.1 Thalassemia Population by Category
2.2 Thalassemia Market by Treatment
2.2.1 Global Bone Marrow Market Forecast by Value
2.2.2 Global Luspatercept Revenue Forecast for Beta-Thalassemia
3. Regional Market Analysis
3.1 The U.S.
3.1.1 The U.S. Beta-Thalassemia Patient Volume Forecast
3.1.2 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume Forecast
3.1.3 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume by Category
3.1.4 The U.S. Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
3.1.5 The U.S. Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
3.1.6 The U.S. Luspatercept Drug Revenue Forecast for Beta-Thalassemia
3.2.1 Europe Beta-Thalassemia Patient Volume Forecast
3.2.2 Europe Beta-Thalassemia Intermedia/Major Patient Volume Forecast
3.2.3 Europe Beta-Thalassemia Intermedia/Major Patient Volume by Category
3.2.4 Europe Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
3.2.5 Europe Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
3.2.6 Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia
4. Market Dynamics
4.1 Growth Drivers
4.2 Key Trends & Developments
4.3 Key Challenges
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 Market Cap Comparison of Key Players
6. Company Profiles
Browse All Latest Pharmaceuticals Market Research Reports at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.
Market Reports Online is a comprehensive online library of more than 100,000 reports, in-depth market research studies on thousands of micro markets and a range of industries. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe. We offer online and offline support services to ensure your research requirements are met on time.
Name: Hrishikesh Patwardhan
Email: Send Email
Phone: + 1 888 391 5441
Release ID: 280883